• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Photocure ASA: Annual Report 2022

    4/12/23 10:11:00 AM ET
    $PHO
    Get the next $PHO alert in real time by email

    OSLO, Norway, April 12, 2023 /PRNewswire/ -- Photocure ASA today announces the publication of the Annual Report and integrated ESG report for 2022.

    The Board of Directors of Photocure ASA has approved the annual accounts for 2022. The financial statements and annual report for the financial year 2022 are together with the ESG report and auditor's report attached to this notice. The ESEF file for 2022 is also attached.

    The documents are enclosed and also made available at the company's website under https://photocure.com/investors-hub/investors-events-and-presentations.

    For further information, please contact:

    Photocure

    CFO Erik Dahl

    Tel: +47 450 55 000

    Email: [email protected]

    About Photocure ASA:

    Photocure: The Bladder Cancer Company delivers transformative solutions to improve the lives of bladder cancer patients. Our unique technology, making cancer cells glow bright pink, has led to better health outcomes for patients worldwide. Photocure is headquartered in Oslo, Norway, and listed on the Oslo Stock Exchange (OSE: PHO). For more information, please visit us at www.photocure.com, www.hexvix.com or www.cysview.com.

    All trademarks mentioned in this release are protected by law and are registered trademarks of Photocure ASA. This information is subject to the disclosure requirements pursuant to sections 5-12 of the Norwegian Securities Trading Act.

    The following files are available for download:

    https://mb.cision.com/Main/17498/3749645/1979906.pdf

    Release

    https://mb.cision.com/Main/17498/3749645/1979907.zip

    Photocure ESEF report 2022.zip

    https://mb.cision.com/Public/17498/3749645/a1982643aaacf296.pdf

    Photocure Annual Report and ESG 2022

     

    Cision View original content:https://www.prnewswire.com/news-releases/photocure-asa-annual-report-2022-301795678.html

    SOURCE Photocure

    Get the next $PHO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PHO

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PHO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Photocure Partner Asieris to present First-ever Results of the international multicenter Phase III clinical Study for Cevira, a non-surgical treatment for cervical HSIL, at the 2024 EUROGIN

    OSLO, Norway, Feb. 22, 2024 /PRNewswire/ --Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) has communicated today that the international multicenter Phase III clinical study of Cevira® (APL-1702), the non-surgical treatment in development for cervical high-grade squamous intraepithelial lesions (HSIL), will be presented for the first time in the form of an oral presentation at the 2024 European Research Organization on Genital Infection and Neoplasia (EUROGIN), held March 13-16 in Stockholm, Sweden: Oral presentation (Abstract No.6802) Photodynamic therapy with APL-1702 for high-grade squamous intraepithelial lesions (HS

    2/22/24 2:51:00 AM ET
    $PHO

    Photocure ASA: Results for the fourth quarter of 2023

    OSLO, Norway, Feb. 21, 2024 /PRNewswire/ -- Photocure ASA (OSE: PHO) today reported Hexvix®/Cysview® revenues of NOK 114.2 million in the fourth quarter of 2023, an increase of 20% over the prior-year period (Q4 2022: NOK 94.9 million), and EBITDA of NOK 29.9 million (NOK -16.9 million) following solid business development for the Company. Total revenues increased 37% in the fourth quarter of 2023 compared to Q4 2022, including a milestone payment from Asieris related to the license agreement for Cevira®. Photocure has an ambition to deliver 40-70 new and upgraded Saphira™ tower installations in 2024, consolidated product revenue growth of 6% to 9% (constant currency), and positive EBITDA ex

    2/21/24 2:15:00 AM ET
    $PHO

    Photocure Partner Asieris announces New Drug Application acceptance for regulatory review of Hexvix in China

    OSLO, Norway, Nov. 29, 2023 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) communicated today that the National Medical Products Administration (NMPA) accepted the new drug application (NDA) for Hexvix® (APL-1706) in China. Hexvix, a pharmaceutical product used in the detection of bladder cancer, was licensed to Asieris by Photocure in January 2021, for the registration and commercialization of Hexvix in mainland China and Taiwan. Results of the Hexvix (APL-1706) Phase III clinical trial in China were presented at the 43rd Congress of the Société Internationale d'Urologie (SIU) last month, as a late-brea

    11/29/23 4:23:00 AM ET
    $PHO